BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24170770)

  • 1. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.
    Ning Y; Gerger A; Zhang W; Hanna DL; Yang D; Winder T; Wakatsuki T; Labonte MJ; Stintzing S; Volz N; Sunakawa Y; Stremitzer S; El-Khoueiry R; Lenz HJ
    Mol Cancer Ther; 2014 Feb; 13(2):528-39. PubMed ID: 24170770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A common gene variant in PLS3 predicts colon cancer recurrence in women.
    Szkandera J; Winder T; Stotz M; Weissmueller M; Langsenlehner T; Pichler M; Samonigg H; Renner W; Gerger A; Absenger G
    Tumour Biol; 2013 Aug; 34(4):2183-8. PubMed ID: 23549633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
    Bohanes P; Yang D; Loupakis F; LaBonte MJ; Gerger A; Ning Y; Lenz C; Lenz F; Wakatsuki T; Zhang W; Benhaim L; El-Khoueiry A; El-Khoueiry R; Lenz HJ
    Pharmacogenomics J; 2015 Jun; 15(3):226-34. PubMed ID: 25487679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.
    Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Rodríguez-Salas N; Burgos E; Ramos D; Calatrava A; Andrada E; Díaz-López E; Sánchez A; Madero R; Cejas P; Feliu J
    Mol Cancer Ther; 2014 Sep; 13(9):2226-37. PubMed ID: 24980946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common cancer stem cell gene variants predict colon cancer recurrence.
    Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ
    Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
    Lurje G; Zhang W; Schultheis AM; Yang D; Groshen S; Hendifar AE; Husain H; Gordon MA; Nagashima F; Chang HM; Lenz HJ
    Ann Oncol; 2008 Oct; 19(10):1734-41. PubMed ID: 18550579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.
    Absenger G; Benhaim L; Szkandera J; Zhang W; Yang D; Labonte MJ; Pichler M; Stotz M; Samonigg H; Renner W; Gerger A; Lenz HJ
    Pharmacogenomics J; 2014 Apr; 14(2):130-4. PubMed ID: 23567490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
    Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
    Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
    Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.
    Szkandera J; Herzog S; Pichler M; Stiegelbauer V; Stotz M; Schaberl-Moser R; Samonigg H; Asslaber M; Lax S; Leitner G; Renner W; Lenz HJ; Berghold A; Gerger A
    Pharmacogenomics J; 2015 Oct; 15(5):391-6. PubMed ID: 25665511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
    Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
    Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis.
    Yokobori T; Iinuma H; Shimamura T; Imoto S; Sugimachi K; Ishii H; Iwatsuki M; Ota D; Ohkuma M; Iwaya T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Toh H; Sato T; Barnard GF; Fukagawa T; Yamamoto S; Nakanishi H; Sasaki S; Miyano S; Watanabe T; Kuwano H; Mimori K; Pantel K; Mori M
    Cancer Res; 2013 Apr; 73(7):2059-69. PubMed ID: 23378342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.
    Lin M; Eng C; Hawk ET; Huang M; Lin J; Gu J; Ellis LM; Wu X
    Cancer; 2012 Dec; 118(24):6188-98. PubMed ID: 22673945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
    Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
    Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
    Benhaim L; Gerger A; Bohanes P; Paez D; Wakatsuki T; Yang D; Labonte MJ; Ning Y; El-Khoueiry R; Loupakis F; Zhang W; Laurent-Puig P; Lenz HJ
    Pharmacogenomics J; 2014 Apr; 14(2):135-41. PubMed ID: 23752739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.
    Páez D; Gerger A; Zhang W; Yang D; Labonte MJ; Benhanim L; Kahn M; Lenz F; Lenz C; Ning Y; Wakatsuki T; Loupakis F; Lenz HJ
    Pharmacogenomics J; 2014 Apr; 14(2):142-50. PubMed ID: 23817222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.
    Phipps AI; Shi Q; Newcomb PA; Nelson GD; Sargent DJ; Alberts SR; Limburg PJ
    J Clin Oncol; 2013 Jun; 31(16):2016-23. PubMed ID: 23547084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
    Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
    Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.